PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer

Samina Qamar; Uzair Bashir Chaudhary

doi:doi:10.11648/j.jctr.20170505.11

| Peer-Reviewed

PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer

Samina Qamar, Uzair Bashir Chaudhary

Published in Journal of Cancer Treatment and Research (Volume 5, Issue 5)

Received: 18 July 2017 Accepted: 11 August 2017 Published: 4 September 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Advanced bladder cancer (BC) has a poor prognosis with historically limited therapeutic options. Immunotherapy has emerged as a viable option for patients with advanced bladder cancer in the second line setting. Immune check point inhibitors have shown promising results in management of this disease. In this review we will discuss the recently evolving role of anti PD-1/PD-L1 inhibitors (programmed cell death protein-1 and programmed death ligand-1) for managing this disease.

Published in	Journal of Cancer Treatment and Research (Volume 5, Issue 5)
DOI	10.11648/j.jctr.20170505.11
Page(s)	71-80
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cancer, Bladder, Immunotherapy, PD-L1, PD-1

References

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb; 66(1): 7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. PMID: 26742998.
[2]	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61; 69-90.
[3]	American cancer society. What are the key statistics about bladder cancer? http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed March 11, 2014.
[4]	Kim WY. The geriatrics and genetics behind bladder cancer. Am Soc Clin Oncol Educ Book. 2014: e192-e195.
[5]	Pinsky CM, Camacho FJ, et al. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep. 1985 Jan; 69(1): 47-53. PMID: 3881177.
[6]	Seront E, Machiels JP. Molecular biology and targeted therapies for urothelial carcinoma. Cancer tret. Rev. 41(4), 341-353 (2015).
[7]	Von dr Maase H, Sengelov L, et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-08.
[8]	De Santis M, Bellmunt J, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2): 191-9. PMID: 22162575.
[9]	Sonpavde G, Sternberg CN, Rosenberg JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional- cell carcinoma of the urothelium. Lancet Oncol 2010; 11: 861-870.
[10]	Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of bladder. Cancer. 2006; 107: 506-513.
[11]	Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013 Jun; 24(6): 1466-72. doi: 10.1093/annonc/mdt 007. PMID: 23419284.
[12]	Pardoll Dm. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
[13]	Sunshine J, taube JM. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23 32-38 (2015).
[14]	Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
[15]	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 56-67.
[16]	Powles T, Eder JP, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528): 558-62.
[17]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-54.
[18]	Petrylak, D, Powles T, et al. (2015) A phase Ia study of MPDL3280a (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33, 2015 (Suppl.): abstract 4501. 2015 ASCO Annual Meeting.
[19]	Loriot Y, Rosenberg JE, Powles TB, et al. Atezolizumab (atezo) in Platinum (plat)- treated locally advanced/ metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Ph II IMvigor210 study. Ann Once. 2016; 27(6): 266-295.
[20]	Balar AV, Galsky MD, Rosenberg JE, et al. IMvigor210 Study Group. ancet. 2017 Jan 7; 389(10064): 67-76. doi: 10.101Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. L 6/S0140-6736(16)32455-2. PMID: 27939400.
[21]	Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10; 34(26): 3119-25. doi: 10.1200/JCO.2016.67.9761. PMID: 27269937.
[22]	Wolchok JD, Kluger H, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133.
[23]	Hammers H, plimack E, Infante J, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) J Clin Oncol 2014; 32: (5s): abstr 4505.
[24]	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3; 348 (6230): 124-128.
[25]	Schumacher TN, Schreiber RD (2015) Neoantigen in cancer immunotherapy. Science 348: 69-74.
[26]	Le DT, Uram JN, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25; 372(26): 2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
[27]	Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res. 2015 Dec 1; 75(23): 5034-45. doi: 10.1158/0008-5472. CAN-14-3098. Epub 2015 Nov 16. PMID: 26573793.
[28]	Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-1964. (PubMed: 17008531).
[29]	Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007 Mar 6; 104(10): 3967-72.
[30]	Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015 Mar; 85(3): 703.e1-6. doi: 10.1016/j.urology.2014.10.020. PMID: 25733301.
[31]	Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemokine gene signature identifies lymph node structure in melanoma; potential for patient selection for immunotherapy? Sci Rep. 2012; 2: 765.
[32]	Callea M, Albiges L, Gupta M, et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10): 1158-64.
[33]	Borghaei H, Smith MR, Campbell KS, Immunotherapy of cancer. Eur. J. Pharmacol. 625(1-3), 41-54(2009).
[34]	Chen DS, Mellman I, Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10.
[35]	Gerlinger m, Catto JW, Orntoft TF, et al. Intratumor heterogeneity in urologic cancers: From molecular evidence to clinical implications. Eur Urol 67: 729-737, 2015.
[36]	Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of bladder and BCG-induced granulomata: association with localized stage progression. Cancer 2007; 109: 1499-1505.
[37]	Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell coregulatory protein expression with clinical outcome following radical cystectomy for urothelial carcinoma of bladder. Eur J Surg Oncol 2014; 40(1): 121-7.
[38]	Nakanishi j, Wada Y, et al. Overexpression of B7-H1 (Pd-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56 (8), 1173-1182 (2007).
[39]	Boorjian SA, Sheinin Y, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008 Aug 1; 14(15): 4800-8.
[40]	Bellmunt J, Mullane SA, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4): 812-7.
[41]	Geraldine Pignot, Constance LE Goux, et al. mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors. 2016 ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr 4523).
[42]	Mukherji D, Jabbour MN, Saroufim M, et al. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker? Clin Genitourin Cancer. 2016 Apr; 14(2): 183-7. doi: 10.1016/j.clgc.2015.12.002. Epub 2015 Dec 17. PMID: 26775720.
[43]	Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2): 152-65. doi: 10.1016/j.ccr.2014.01.009. PMID: 24525232.
[44]	Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA 2014; 64: 9-29.
[45]	Ludwig AT, Moore JM, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 2004 May 15; 64(10): 3386-90. PMID: 15150089.
[46]	Michael E. Hurwitz, Daniel Peter Petrylak, et al. J Clin Oncol 33, 2015 (suppl; abstr e15504) 2015 ASCO Annual Meeting.
[47]	De Santis M, Bellmunt J, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2): 191-9. doi: 10.1200/JCO.2011.37.3571.
[48]	Bellmunt J, von der Maase H, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 1; 30(10): 1107-13. doi: 10.1200/JCO.2011.38.6979. PMID: 22370319.
[49]	Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb; 18(2): 212-220. doi: 10.1016/S1470-2045(17)30007-4. PMID: 28081914.
[50]	Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010 Sep; 11(9): 861-70. doi: 10.1016/S1470-2045(10)70086-3. Review. PMID: 20537950.
[51]	Bellmunt J, de Wit R, et al. KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16; 376(11): 1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.
[52]	Balar A, Bellmunt J, O’ Donnell PH, et al. Pembrolizumab (pembro) as a first line therapy for advanced/ resectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. European society for medical oncology. Copenhagen, Denmark: Proceeding of ESMO; 2016. Abstr LBA32_PR.
[53]	Vandeveer AJ, Fallon JK, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May; 4(5): 452-62. doi: 10.1158/2326-6066. CIR-15-0176. Epub 2016 Feb 26. PMID: 26921031.
[54]	Apolo AB, Infante JR, Hamid O, et al. Safety, clinical activity, ad PDL1 expression of avelumab (MSB0010718), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase Ib trial. J Clin Oncol 2016; 34; abstr 367.
[55]	Sharma P, Callahan MK, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016 Nov; 17(11): 1590-1598. doi: 10.1016/S1470-2045(16)30496-X. PMID: 27733243.
[56]	Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Jan 25. pii: S1470-2045(17)30065-7. doi: 10.1016/S1470-2045(17)30065-7. PMID: 28131785.
[57]	Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan; 27(1): 49-61. doi: 10.1093/annonc/mdv509. Review.
[58]	Sharma P, Callahan MK, Calvo E, et al. Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: first results from the phase I/II checkmate 032 study. Society for immunotherapy of cancer (SITC) annual meeting. National Harbor, MD, 2016; abstract 449.
[59]	Massard C, Gordon MS, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10; 34(26): 3119-25. doi: 10.1200/JCO.2016.67.9761.

Cite This Article

Plain Text BibTeX RIS

APA Style

Samina Qamar, Uzair Bashir Chaudhary. (2017). PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. Journal of Cancer Treatment and Research, 5(5), 71-80. https://doi.org/10.11648/j.jctr.20170505.11

Copy | Download

ACS Style

Samina Qamar; Uzair Bashir Chaudhary. PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. J. Cancer Treat. Res. 2017, 5(5), 71-80. doi: 10.11648/j.jctr.20170505.11

Copy | Download

AMA Style

Samina Qamar, Uzair Bashir Chaudhary. PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. J Cancer Treat Res. 2017;5(5):71-80. doi: 10.11648/j.jctr.20170505.11

Copy | Download

@article{10.11648/j.jctr.20170505.11,
  author = {Samina Qamar and Uzair Bashir Chaudhary},
  title = {PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {5},
  number = {5},
  pages = {71-80},
  doi = {10.11648/j.jctr.20170505.11},
  url = {https://doi.org/10.11648/j.jctr.20170505.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20170505.11},
  abstract = {Advanced bladder cancer (BC) has a poor prognosis with historically limited therapeutic options. Immunotherapy has emerged as a viable option for patients with advanced bladder cancer in the second line setting. Immune check point inhibitors have shown promising results in management of this disease. In this review we will discuss the recently evolving role of anti PD-1/PD-L1 inhibitors (programmed cell death protein-1 and programmed death ligand-1) for managing this disease.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
AU  - Samina Qamar
AU  - Uzair Bashir Chaudhary
Y1  - 2017/09/04
PY  - 2017
N1  - https://doi.org/10.11648/j.jctr.20170505.11
DO  - 10.11648/j.jctr.20170505.11
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 71
EP  - 80
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20170505.11
AB  - Advanced bladder cancer (BC) has a poor prognosis with historically limited therapeutic options. Immunotherapy has emerged as a viable option for patients with advanced bladder cancer in the second line setting. Immune check point inhibitors have shown promising results in management of this disease. In this review we will discuss the recently evolving role of anti PD-1/PD-L1 inhibitors (programmed cell death protein-1 and programmed death ligand-1) for managing this disease.
VL  - 5
IS  - 5
ER  -

Copy | Download

Author Information

Samina Qamar

Division of Geriatrics, Gerontology & Palliative medicine, University of Texas Health Science Center, San Antonio, USA
Uzair Bashir Chaudhary

Division of Hematology & Oncology, University of California San Francisco, Fresno, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Samina Qamar, Uzair Bashir Chaudhary. (2017). PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. Journal of Cancer Treatment and Research, 5(5), 71-80. https://doi.org/10.11648/j.jctr.20170505.11

Copy | Download

ACS Style

Samina Qamar; Uzair Bashir Chaudhary. PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. J. Cancer Treat. Res. 2017, 5(5), 71-80. doi: 10.11648/j.jctr.20170505.11

Copy | Download

AMA Style

Samina Qamar, Uzair Bashir Chaudhary. PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer. J Cancer Treat Res. 2017;5(5):71-80. doi: 10.11648/j.jctr.20170505.11

Copy | Download

@article{10.11648/j.jctr.20170505.11,
  author = {Samina Qamar and Uzair Bashir Chaudhary},
  title = {PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {5},
  number = {5},
  pages = {71-80},
  doi = {10.11648/j.jctr.20170505.11},
  url = {https://doi.org/10.11648/j.jctr.20170505.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20170505.11},
  abstract = {Advanced bladder cancer (BC) has a poor prognosis with historically limited therapeutic options. Immunotherapy has emerged as a viable option for patients with advanced bladder cancer in the second line setting. Immune check point inhibitors have shown promising results in management of this disease. In this review we will discuss the recently evolving role of anti PD-1/PD-L1 inhibitors (programmed cell death protein-1 and programmed death ligand-1) for managing this disease.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
AU  - Samina Qamar
AU  - Uzair Bashir Chaudhary
Y1  - 2017/09/04
PY  - 2017
N1  - https://doi.org/10.11648/j.jctr.20170505.11
DO  - 10.11648/j.jctr.20170505.11
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 71
EP  - 80
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20170505.11
AB  - Advanced bladder cancer (BC) has a poor prognosis with historically limited therapeutic options. Immunotherapy has emerged as a viable option for patients with advanced bladder cancer in the second line setting. Immune check point inhibitors have shown promising results in management of this disease. In this review we will discuss the recently evolving role of anti PD-1/PD-L1 inhibitors (programmed cell death protein-1 and programmed death ligand-1) for managing this disease.
VL  - 5
IS  - 5
ER  -

Copy | Download